Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Kenyon

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Clinical Reviews in Allergy & Immunology|October 24, 2003
Severe asthmaNicholas J Kenyon, Nizar N Jarjour
Annals of Intensive Care|October 16, 2012
A fresh look at paralytics in the critically ill: real promise and real concernDavid Price, Nicholas J Kenyon, Nicholas Stollenwerk
Toxicology and Applied Pharmacology|August 14, 2003
Susceptibility to ovalbumin-induced airway inflammation and fibrosis in inducible nitric oxide synthetase-deficient mice: mechanisms and consequencesNicholas J Kenyon, Kishorchandra Gohil, Jerold A Last
Ebiomedicine|January 8, 2021
A breath of fresh air - the potential for COVID-19 breath diagnosticsCristina E Davis, Michael Schivo, Nicholas J Kenyon
Drug Metabolism Letters|January 5, 2011
Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further researchAmir A Zeki, Nicholas J Kenyon, Tzipora Goldkorn
Toxicology and Applied Pharmacology|March 18, 2003
Airway fibrosis in a mouse model of airway inflammationNicholas J Kenyon, Rachel W Ward, Jerold A Last
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2008
Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthmaGertrud U Schuster, Nicholas J Kenyon, Charles B Stephensen
Clinical Reviews in Allergy & Immunology|March 23, 2011
The adult asthmaticAmir A Zeki, Nicholas J Kenyon, Ken Yoneda, et al.
Inhalation Toxicology|January 28, 2004
Ovalbumin-induced airway inflammation and fibrosis in mice also exposed to ozoneJerold A Last, Rachel Ward, Lisa Temple, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 14, 2018
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthmaJenny Lam, Joel W Hay, Jonathan Salcedo, et al.
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Clinical Reviews in Allergy & Immunology|October 24, 2003
Severe asthmaNicholas J Kenyon, Nizar N Jarjour
Annals of Intensive Care|October 16, 2012
A fresh look at paralytics in the critically ill: real promise and real concernDavid Price, Nicholas J Kenyon, Nicholas Stollenwerk
Toxicology and Applied Pharmacology|August 14, 2003
Susceptibility to ovalbumin-induced airway inflammation and fibrosis in inducible nitric oxide synthetase-deficient mice: mechanisms and consequencesNicholas J Kenyon, Kishorchandra Gohil, Jerold A Last
Ebiomedicine|January 8, 2021
A breath of fresh air - the potential for COVID-19 breath diagnosticsCristina E Davis, Michael Schivo, Nicholas J Kenyon
Drug Metabolism Letters|January 5, 2011
Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further researchAmir A Zeki, Nicholas J Kenyon, Tzipora Goldkorn
Toxicology and Applied Pharmacology|March 18, 2003
Airway fibrosis in a mouse model of airway inflammationNicholas J Kenyon, Rachel W Ward, Jerold A Last
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2008
Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthmaGertrud U Schuster, Nicholas J Kenyon, Charles B Stephensen
Clinical Reviews in Allergy & Immunology|March 23, 2011
The adult asthmaticAmir A Zeki, Nicholas J Kenyon, Ken Yoneda, et al.
Inhalation Toxicology|January 28, 2004
Ovalbumin-induced airway inflammation and fibrosis in mice also exposed to ozoneJerold A Last, Rachel Ward, Lisa Temple, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 14, 2018
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthmaJenny Lam, Joel W Hay, Jonathan Salcedo, et al.
Pageof 12